Bellicum Pharma (BLCM): Raising PT On Accelerated BPX-501 Approval - Piper Jaffray

August 9, 2016 9:11 AM EDT
Get Alerts BLCM Hot Sheet
Price: $16.59 --0%

Rating Summary:
    8 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 24 | New: 11
Trade BLCM Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Bellicum Pharma (NASDAQ: BLCM) announced a strategy to pursue a rapid path of approval for BPX-501, the company's allogeneic T-cell add-back with an "off switch". The EMA has agreed data that an expanded BP-004 study could support approval under "exceptional circumstances" for pediatric patients in malignant and nonmalignant settings. The analyst e believes BPX-501 is a highly differentiated program and the broad ability to control cells is increasingly attractive in a CAR-T field that has suffered some safety concerns.

The company will also be advancing a CD19 targeting CAR-T with the CaspaCIDe "off-switch" which the analyst believes will be competitive.

Piper Jaffray analyst, Joshua Schimmer, reiterated his Overweight rating but rapid progress of BPX-501 towards approval pushes accelerated EU approval forward into 2018 resulting in a PT change from $25 to $31.

For an analyst ratings summary and ratings history on Bellicum Pharmaceuticals click here. For more ratings news on Bellicum Pharmaceuticals click here.

Shares of Bellicum Pharmaceuticals closed at $17.05 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Piper Jaffray, Joshua Schimmer

Add Your Comment